Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma-Reference-Cited by-同舟云学术

Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma

Published:2007-01-24 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Sasse Andre D¹,Sasse Emma C¹,Clark Luciana GO²,Ulloa Luciana³,Clark Otavio Augusto Camara⁴

Affiliation:

1. UNICAMP (Universidade Estadual de Campinas); Internal Medicine; Av Dr. Luiz de Tella 1515 Cidade Universitaria Campinas Sao Paulo Brazil 13083 000

2. Hospital Celso Pierro/PUC-Campinas e Instituto do Radium de Campinas; Oncology; Av. Dr. Luiz de Tella 970 Cidade Univeristaria Campinas São Paulo Brazil CEP 13083 000

3. Public Health Unit; Blumenau-SC Brazil

4. Scientific Solutions in Healthcare; Evidências; Av. Dr. Luis de Tella Campinas São Paulo Brazil 1570

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD005413.pub2/fullpdf

Reference63 articles.

1. Atkins MB Lee S Flaherty LE Sosman JA Sondak VK Kirkwood JM A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial In: ASCO Annual Meeting; 2003; 2003. p ASCO Annual Meeting - Proceedings 2003 Abstract 2847

2. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM);Atzpodien;British journal of cancer,2002

3. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma;Bajetta;Journal of clinical oncology : official journal of the American Society of Clinical Oncology,1994

4. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma;Danson;Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2003

5. Del Vecchio M Bajetta E Vitali M Gattinoni L Santinami M Daponte A Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts). In: ASCO Annual Meeting; 2003; 2003. p ASCO Annual Meeting - Proceedings 2003 Abstract 2849

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fortuitous discovery of melanomas in the ENT Department – a histopathological and immunohistochemical study;Romanian Journal of Morphology and Embryology;2021-06-25

2. Outcome assessment in dermatology clinical trials and cochrane reviews: call for a dermatology‐specific outcome taxonomy;Journal of the European Academy of Dermatology and Venereology;2020-09-11

3. Inherited variations in human pigmentation-related genes modulate cutaneous melanoma risk and clinicopathological features in Brazilian population;Scientific Reports;2020-07-22

Treatment of Advanced/Metastatic Melanoma in the United States and Western Europe: Results of the CancerMPact Survey

;Cancer Management and Research;2020-07

5. A twelve-gene signature for survival prediction in malignant melanoma patients;Annals of Translational Medicine;2020-03